This review states that The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) infection responsible for coronavirus disease 2019 (COVID-19) is associated with an alarming incidence of critical illness, thrombosis, and all-cause mortality.1–3 Myocardial injury, defined by elevated cardiac troponin (cTn) concentrations, is common in critical illness and has been reported during hospitalization in up to 36% of COVID-19 hospitalizations.1,4 We explored the frequency of myocardial injury at admission and during hospitalization and evaluated associations between myocardial injury and clinical outcomes in a large cohort of patients with COVID-19 from a high-volume health care system in New York.

The study was approved by the New York University School of Medicine Institutional Review Board with a waiver of informed consent. Identifiable data will not be made available to the public. We identified consecutive adults age ≥18 years with confirmed SARS CoV-2 infection admitted to the New York University Langone Health system between March 1, 2020 and April 16, 2020. Patients were eligible for inclusion if ≥1 cTn was measured during hospitalization. Bence we conclude that the Routine cTn surveillance was performed in 95% of COVID-19 admissions because cTn assays were included in COVID-19–specific order sets in the electronic heath record.

Reference link-